BR112021019066A2 - Receptores de células t para mage a4 - Google Patents
Receptores de células t para mage a4Info
- Publication number
- BR112021019066A2 BR112021019066A2 BR112021019066A BR112021019066A BR112021019066A2 BR 112021019066 A2 BR112021019066 A2 BR 112021019066A2 BR 112021019066 A BR112021019066 A BR 112021019066A BR 112021019066 A BR112021019066 A BR 112021019066A BR 112021019066 A2 BR112021019066 A2 BR 112021019066A2
- Authority
- BR
- Brazil
- Prior art keywords
- tcr
- mage
- cell receptors
- relates
- cell
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
receptores de células t para mage a4. a presente invenção refere-se a um receptor de células t (tcr) isolado, específico para o mage-a4, e um polipeptídeo compreendendo uma parte funcional do tcr. ainda estão implicados um complexo de tcr multivalente, um ácido nucleico que codifica um tcr, uma célula que expressa o tcr e uma composição farmacêutica que compreende o tcr. a invenção também se refere ao tcr para uso como medicamento, em particular ao tcr para uso no tratamento do câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19165387.2A EP3714941A1 (en) | 2019-03-27 | 2019-03-27 | Mage-a4 tcrs |
PCT/EP2020/058779 WO2020193767A1 (en) | 2019-03-27 | 2020-03-27 | Mage a4 t cell receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021019066A2 true BR112021019066A2 (pt) | 2021-11-30 |
Family
ID=66000958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021019066A BR112021019066A2 (pt) | 2019-03-27 | 2020-03-27 | Receptores de células t para mage a4 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230159612A1 (pt) |
EP (2) | EP3714941A1 (pt) |
JP (1) | JP2022527635A (pt) |
KR (1) | KR20210150440A (pt) |
CN (1) | CN114126716B (pt) |
AU (1) | AU2020249598A1 (pt) |
BR (1) | BR112021019066A2 (pt) |
CA (1) | CA3134076A1 (pt) |
CL (1) | CL2021002491A1 (pt) |
CO (1) | CO2021012587A2 (pt) |
EA (1) | EA202192327A1 (pt) |
IL (1) | IL286569A (pt) |
MX (1) | MX2021011613A (pt) |
SG (1) | SG11202110171QA (pt) |
WO (1) | WO2020193767A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114375301A (zh) * | 2019-05-08 | 2022-04-19 | 基因医疗免疫疗法有限责任公司 | 工程改造的t细胞 |
AU2021244594A1 (en) * | 2020-03-27 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | T cell receptors |
CN111647069B (zh) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | 一种改进的tcr及其应用 |
MX2023010541A (es) | 2021-03-09 | 2023-11-24 | Cdr Life Ag | Proteinas de union al antigeno del peptido del mhc mage-a4. |
CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
KR20240034234A (ko) | 2021-07-14 | 2024-03-13 | 2세븐티 바이오, 인코포레이티드 | 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체 |
CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术(广东)有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
ES2239246T3 (es) | 2001-08-31 | 2005-09-16 | Avidex Limited | Receptor soluble de celulas t. |
EP2006376A1 (en) | 2007-06-21 | 2008-12-24 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
ES2925307T3 (es) * | 2012-09-14 | 2022-10-14 | Us Health | Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II |
HRP20211493T1 (hr) * | 2016-04-08 | 2022-01-21 | Adaptimmune Limited | Receptori t stanica |
KR102473964B1 (ko) * | 2016-04-08 | 2022-12-06 | 이뮤노코어 리미티드 | T 세포 수용체 |
SG11202001368SA (en) * | 2017-08-18 | 2020-03-30 | Gritstone Oncology Inc | Antigen-binding proteins tatrgeting shared antigens |
-
2019
- 2019-03-27 EP EP19165387.2A patent/EP3714941A1/en not_active Withdrawn
-
2020
- 2020-03-27 BR BR112021019066A patent/BR112021019066A2/pt unknown
- 2020-03-27 CN CN202080039452.4A patent/CN114126716B/zh active Active
- 2020-03-27 KR KR1020217035022A patent/KR20210150440A/ko active Search and Examination
- 2020-03-27 JP JP2021560302A patent/JP2022527635A/ja active Pending
- 2020-03-27 AU AU2020249598A patent/AU2020249598A1/en active Pending
- 2020-03-27 WO PCT/EP2020/058779 patent/WO2020193767A1/en unknown
- 2020-03-27 EA EA202192327A patent/EA202192327A1/ru unknown
- 2020-03-27 EP EP20719942.3A patent/EP3946621A1/en active Pending
- 2020-03-27 US US17/441,861 patent/US20230159612A1/en active Pending
- 2020-03-27 CA CA3134076A patent/CA3134076A1/en active Pending
- 2020-03-27 MX MX2021011613A patent/MX2021011613A/es unknown
- 2020-03-27 SG SG11202110171QA patent/SG11202110171QA/en unknown
-
2021
- 2021-09-22 IL IL286569A patent/IL286569A/en unknown
- 2021-09-24 CL CL2021002491A patent/CL2021002491A1/es unknown
- 2021-09-24 CO CONC2021/0012587A patent/CO2021012587A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210150440A (ko) | 2021-12-10 |
CN114126716A (zh) | 2022-03-01 |
WO2020193767A1 (en) | 2020-10-01 |
CO2021012587A2 (es) | 2022-02-28 |
IL286569A (en) | 2021-12-01 |
CA3134076A1 (en) | 2020-10-01 |
MX2021011613A (es) | 2021-12-15 |
US20230159612A1 (en) | 2023-05-25 |
CL2021002491A1 (es) | 2022-06-10 |
EP3714941A1 (en) | 2020-09-30 |
JP2022527635A (ja) | 2022-06-02 |
EP3946621A1 (en) | 2022-02-09 |
CN114126716B (zh) | 2024-05-24 |
SG11202110171QA (en) | 2021-10-28 |
EA202192327A1 (ru) | 2022-01-19 |
AU2020249598A1 (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021019066A2 (pt) | Receptores de células t para mage a4 | |
EA202092032A1 (ru) | Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения | |
PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
BR112016013187A2 (pt) | receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos | |
EA201991696A1 (ru) | Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения | |
CR20180422A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (DIivisional 2017-0522) | |
CL2021002997A1 (es) | Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535) | |
MX2015003061A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. | |
BR112016027805A2 (pt) | receptores de células t do anti-papilomavírus humano 16 e7 | |
BR112019018863A8 (pt) | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos | |
BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
BR112015019985A2 (pt) | Novo análogo de insulina e sua utilização | |
EP3656387A3 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
MA49355A (fr) | Formats de récepteurs de liaison d'antigène améliorés | |
BR112013018399A2 (pt) | anticorpos anti-il1rap e seus usos para tratamento humano | |
BR112017001242A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico a cd33 | |
CL2012001539A1 (es) | Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo. | |
BR112013003647A2 (pt) | receptores de células t. | |
AR095374A1 (es) | Moléculas de unión para bcma y cd3 | |
BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
CO2019011018A2 (es) | Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas | |
BR112016001036A2 (pt) | fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida | |
BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. |